CA2181241A1 - Process for Solubilizing Difficultly Soluble Pharmaceutical Actives - Google Patents

Process for Solubilizing Difficultly Soluble Pharmaceutical Actives

Info

Publication number
CA2181241A1
CA2181241A1 CA2181241A CA2181241A CA2181241A1 CA 2181241 A1 CA2181241 A1 CA 2181241A1 CA 2181241 A CA2181241 A CA 2181241A CA 2181241 A CA2181241 A CA 2181241A CA 2181241 A1 CA2181241 A1 CA 2181241A1
Authority
CA
Canada
Prior art keywords
soluble pharmaceutical
pharmaceutical actives
difficultly soluble
solubilizing
solubilizing difficultly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2181241A
Other languages
French (fr)
Other versions
CA2181241C (en
Inventor
Dadi Jamshed Dhabhar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Dadi Jamshed Dhabhar
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dadi Jamshed Dhabhar, The Procter & Gamble Company filed Critical Dadi Jamshed Dhabhar
Publication of CA2181241A1 publication Critical patent/CA2181241A1/en
Application granted granted Critical
Publication of CA2181241C publication Critical patent/CA2181241C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Abstract

A process for improving the solubility of difficultly soluble pharmaceutical actives in a mixture of polyethy1ene glycol and propylene glycol by using a polyvinylpyrrolidone with a specific viscosity average molecular weight of from about 5,000 to about 25,000.
CA002181241A 1994-01-24 1995-01-24 Process for solubilizing difficultly soluble pharmaceutical actives Expired - Fee Related CA2181241C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18557694A 1994-01-24 1994-01-24
US185,576 1994-01-24
PCT/US1995/001018 WO1995019759A1 (en) 1994-01-24 1995-01-24 Process for solubilizing difficultly soluble pharmaceutical actives

Publications (2)

Publication Number Publication Date
CA2181241A1 true CA2181241A1 (en) 1995-07-27
CA2181241C CA2181241C (en) 2000-04-25

Family

ID=22681571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002181241A Expired - Fee Related CA2181241C (en) 1994-01-24 1995-01-24 Process for solubilizing difficultly soluble pharmaceutical actives

Country Status (14)

Country Link
EP (1) EP0741560A1 (en)
JP (1) JPH09508128A (en)
CN (1) CN1138827A (en)
AU (1) AU706890B2 (en)
BR (1) BR9506564A (en)
CA (1) CA2181241C (en)
CZ (1) CZ210496A3 (en)
FI (1) FI962948A (en)
MX (1) MX9602955A (en)
NO (1) NO963052L (en)
NZ (1) NZ279443A (en)
PL (1) PL315635A1 (en)
SK (1) SK96196A3 (en)
WO (1) WO1995019759A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998058637A1 (en) * 1996-06-20 1998-12-30 Mcneil-Ppc Acetaminophen and diphenhydramine analgesics
ZA975444B (en) * 1996-06-20 1998-12-21 Mcneil Ppc Inc Acetaminophen and meclizine hydrochloride analgesics
FR2751875B1 (en) * 1996-08-05 1998-12-24 Scr Newpharm NOVEL STABLE LIQUID FORMULATIONS BASED ON PARACETAMOL AND THEIR METHOD OF PREPARATION
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
US6365180B1 (en) * 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
WO1999036060A1 (en) 1998-01-20 1999-07-22 Applied Analytical Industries, Inc. Oral liquid compositions
US20020086878A1 (en) * 1999-01-11 2002-07-04 Douglas Joseph Dobrozsi Compositions having improved stability
US20020082307A1 (en) * 1999-01-11 2002-06-27 Dobrozsi Douglas Joseph Compositions having improved stability
US6846495B2 (en) 1999-01-11 2005-01-25 The Procter & Gamble Company Compositions having improved delivery of actives
US6211246B1 (en) 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
FR2796843B1 (en) * 1999-07-29 2003-05-09 So Ge Val Sa CONCENTRATED AND STABILIZED ANTIPYRETIC COMPOSITION FOR VETERINARY USE INTENDED TO BE INCORPORATED IN ANIMAL FEEDING AS WELL AS A METHOD OF INCORPORATING THIS COMPOSITION INTO ANIMAL BEVERAGE WATER
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
DE10011032A1 (en) * 2000-03-07 2001-09-13 Bayer Ag Stable solutions of acetylsalicylic acid in mixture of organic solvent and water, useful for topical treatment of pain, especially pain associated with herpes zoster
KR20020069387A (en) * 2001-02-26 2002-09-04 진양제약주식회사 Mixing method of composition containing doxylamine succinate and soft capsule preparation containing the composition
CA2455939C (en) * 2001-07-31 2011-03-22 Wyeth Llc Sucralose formulations to mask unpleasant tastes
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
CN100379406C (en) * 2003-09-22 2008-04-09 北京德众万全药物技术开发有限公司 Method for preparing tiny pellets of difficult soluble drugs and formulation containing the pellets
US8333989B2 (en) * 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
DE102005053066A1 (en) 2005-11-04 2007-05-10 Basf Ag Use of copolymers as solubilizers for sparingly water-soluble compounds
WO2007065846A2 (en) * 2005-12-09 2007-06-14 Basf Se Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilisers for poorly water-soluble compounds
US8637076B2 (en) 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
JP2008184430A (en) * 2007-01-30 2008-08-14 Ss Pharmaceut Co Ltd Soft capsule
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
SI3158991T1 (en) 2010-01-28 2021-10-29 Eagle Pharmaceuticals Inc Formulations of bendamustine
ES2943668T3 (en) 2012-03-20 2023-06-15 Eagle Pharmaceuticals Inc Bendamustine liquid compositions for use in a method of treating conditions responsive to bendamustine in patients requiring reduced volumes for administration
FI2827862T3 (en) 2012-03-20 2024-02-13 Eagle Pharmaceuticals Inc Formulations of bendamustine
CA2898408C (en) * 2013-02-28 2018-01-02 Pfizer Inc. Enhanced stability of novel liquid compositions
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
TWI586379B (en) * 2015-06-29 2017-06-11 永信藥品工業股份有限公司 Method of preparing very slightly soluble drug with solid dosage form
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives

Also Published As

Publication number Publication date
FI962948A0 (en) 1996-07-23
JPH09508128A (en) 1997-08-19
CZ210496A3 (en) 1996-12-11
FI962948A (en) 1996-07-23
NO963052D0 (en) 1996-07-22
MX9602955A (en) 1997-06-28
SK96196A3 (en) 1997-03-05
EP0741560A1 (en) 1996-11-13
CA2181241C (en) 2000-04-25
NO963052L (en) 1996-09-24
CN1138827A (en) 1996-12-25
PL315635A1 (en) 1996-11-25
BR9506564A (en) 1997-09-02
WO1995019759A1 (en) 1995-07-27
NZ279443A (en) 1998-04-27
AU706890B2 (en) 1999-07-01
AU1607595A (en) 1995-08-08

Similar Documents

Publication Publication Date Title
CA2181241A1 (en) Process for Solubilizing Difficultly Soluble Pharmaceutical Actives
CA2172616A1 (en) Tropyl 7-azaindol-3-ylcarboxyamides as antitussive agent
EP0695171A1 (en) Lyospheres comprising gonadotropin
PL300194A1 (en) Interferon conjugate, method of obtaining same and pharmaceutical composition containing it
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
IL84446A0 (en) 3-pyrrolidinylthio-1-azabicyclo-(3.2.0)hept-2-ene-2-carboxylic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
AU2191192A (en) Process for solubilizing difficultly soluble pharmaceutical actives
EP0645136A3 (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation.
CA2114136A1 (en) Gallium (iii) complexes, process for their obtention and pharmaceutical compositions containing them
HUT61554A (en) Process for producing 2,8-dioxabicyclo/3.2.1/octane derivatives and pharmaceutical compositions comprising same
CA2041417A1 (en) Treatment of pancreatic disease with 15-keto-prostaglandin compounds
IL97784A0 (en) 24-oxa derivatives in the vitamin d series,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0391644A3 (en) Aryl-substituted rhodanine derivatives
CA2100126A1 (en) 5,10-Methylenetetrahydrofolic Acid-Cyclodextrin Inclusion Compounds
AU7239794A (en) Process for preparing 5,8-dihydronaphthoquinone derivatives, novel 5,8-dihydronaphthoquinone derivatives and their use as anticancer agent
CA2162154A1 (en) Use of a transition metal complex for the treatment of septic shock
ZA9610460B (en) New phenylamidine derivatives, processes for preparing them and their use as pharmaceutical compositions.
CA2356959A1 (en) Water-insoluble drug delivery system
HUP9900987A3 (en) Camptothecin derivatives process for their preparation, use thereof as antitumor agents and pharmaceutical compositions containing them
HUP9701660A3 (en) 10,13,15-trioxatricyclo[9.2.1.1.9.6]pentadekanon derivatives, process for producing them, and pharmaceutical compositions containing them
HU9403383D0 (en) Diamine salts of clavulanic acid
CA2123367A1 (en) Anti-Allergic Pharmaceutical Composition for Ophthalmic Topical Administration
HK1010537A1 (en) Method of preparing norbenzomorphane as an intermediate in the preparation of pharmaceutically useful benzomorphane derivatives, in particular (-)-(1r,5s,2"r)-3'-hydroxy-2-(2-methoxypropyl)-5,9,9,-trimethyl-6,7-benzomorphane.
GB9310075D0 (en) New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed